June 1, 1973Circulation
Electrophysiologic Properties of Diphenylhydantoin
Key result
Intravenous diphenylhydantoin showed varied effects on A-V nodal conduction, inconsistent effects in the atrium, and consistent shortening of the refractory period of the His-Purkinje system.
Why the study?
Does intravenous diphenylhydantoin alter electrophysiologic properties of the A-V conducting system in human subjects?
Population
14 subjects undergoing His bundle recordings
Comparison
Diphenylhydantoin (DPH) 5-10 mg/kg intravenously vs Baseline (prior to DPH administration)
Design
Case_series
Follow-up
within 10 min of drug administration
Authors
Discussion
Loading...
Member takes
Implication
May differentiate diphenylhydantoin from quinidine-like agents; leaves open confirmation in controlled electrophysiology studies.
Structured PICO
Does intravenous diphenylhydantoin alter electrophysiologic properties of the A-V conducting system in human subjects?
P
Population
14 subjects undergoing His bundle recordings to study the electrophysiologic properties of intravenous diphenylhydantoin.
I
Intervention
Diphenylhydantoin (DPH) 5-10 mg/kg intravenously
C
Comparator
Baseline (prior to DPH administration)
O
Outcome
Electrophysiologic properties including conduction through the A-V conducting system and refractory periodssurrogate
Intravenous diphenylhydantoin consistently shortens the refractory period of the His-Purkinje system, distinguishing its electrophysiologic profile from other antiarrhythmic drugs like quinidine and procainamide.
Cite This Study
Caracta et al. (1973) studied this question. Diphenylhydantoin (DPH) was evaluated on Electrophysiologic properties (conduction and refractory periods). Intravenous diphenylhydantoin showed varied effects on A-V nodal conduction, inconsistent effects in the atrium, and consistent shortening of the refractory period of the His-Purkinje system.